Skip to content

Zevra Therapeutics

US · ZVRA #3562 by market cap
8.76 -0.31 -3.42%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 8.90 -1.87%
After-hours 8.68 -0.87%
Overnight 9.00 -0.77%
14.758.768.762026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ZVRA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -14.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 11.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A+

The radar needs all six factors. Available grades are shown below.

Valuation B

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 7.2x Better than 92%
Forward P/E 10.6x Better than 76%
Price / Sales 3.7x Better than 33%
P/E vs own 5-yr range 82nd pctl Better than 24%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 84.5% Better than 93%
Operating margin -4.0% Better than 18%
Net margin 78.2% Better than 99%
Return on equity 85.7% Better than 97%
Return on invested capital 53.0% Better than 99%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -26.2% Better than 22%
6-month return -12.7% Better than 36%
12-month return (ex latest month) 14.1% Better than 52%
Distance below 52-week high 41.7% Better than 26%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.7x Better than 88%
Debt to assets 22.2% Better than 53%
Interest coverage 11.9x Better than 75%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 191.1% Better than 94%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -3.52%
1M -16.33%
3M -26.32%
6M -14.45%
YTD -2.23%
1Y -3.20%
3Y +95.54%
5Y +4.29%

Key statistics

Price & volume

Prev close
9.07
Open
8.89
Day range
8.70 - 9.20
Avg price
8.82
Volume
1.15M
Turnover
10.17M
Amplitude
5.51%
52-week range
8.01 - 15.04

Valuation

P/E
6.49
P/E (TTM)
7.18
P/B
2.18
EPS
1.35
Net profit
80.33M
Net assets
238.91M

Share structure

Market cap
521.26M
Float cap
472.88M
Shares out
59.50M
Float shares
53.98M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 11% of range
8.01 15.04

41.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-680.08K net over the window

Short interest

Shares short
6.56M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Zevra Therapeutics (ZVRA)?

Zevra Therapeutics last traded at 8.76. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Zevra Therapeutics's market cap?

About 521.26M.

What is the P/E ratio of Zevra Therapeutics?

The trailing twelve-month P/E is 7.18. The Valuation tab shows it against the stock's own five-year range.

Does Zevra Therapeutics pay a dividend?

Zevra Therapeutics does not currently pay a regular dividend.

Is Zevra Therapeutics a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 25.50, which implies 191.1% upside from the current price. This is not investment advice.

What is Zevra Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Zevra Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:31 · For reference only, not investment advice and not tailored to your situation.

Zevra Therapeutics discussion 0 comments

Add a comment